The origin of 1H NMR-visible triacylglycerol in human neutrophils. Highfatty acid environments result in preferential sequestration of palmitic acid into plasma membrane triacylglycerol.
Human neutrophils incubated for 1 h in vitro with 10% commercial pooled, human serum containing high levels of free fatty acids (1141 microM) displayed a distinct lipid signal, typical of triacylglycerol, in the 1H NMR spectrum. Concurrently their plasma membrane triacylglycerol mass increased 4.6-fold with a selective rise in the content of palmitic and linoleic acids. Although qualitatively similar, these effects were much greater than those observed after incubating neutrophils with 50 microg.mL-1 of lipopolysaccharide in the presence of 10% AB serum with normal free fatty acid content (345 microM, LPS/S). Incubation of neutrophils with an artificial mixture of free fatty acids at concentrations found in commercial serum, or with the fatty acid fraction isolated from commercial serum increased the 1H NMR-detectable triacylglycerol. The signal intensity of the 1H NMR-detectable triacylglycerol depended on the triacylglycerol composition, and correlated with increased membrane triacylglycerol mass. Cellular uptake of 3H-labelled palmitic or oleic acids increased in the presence of commercial serum but not with LPS/S, with little contribution in either case to the triacylglycerol pool that increased in mass. Pulse-chase experiments demonstrated that with LPS/S and commercial serum, radiolabelled palmitic acid was preferentially incorporated into triacylglycerol located in the plasma membrane. This process could occur at the plasma membrane, as cytoplasts efficiently convert exogenous fatty acids into triacylglycerol. We propose that LPS/S and serum containing high levels of free fatty acid, important in conditions of sepsis and inflammation, may facilitate the sequestration of palmitic acid into triacylglycerol by different pathways. This triacylglycerol originates from exogenous and endogenous free fatty acids, is 1H NMR-visible, and may have a role in regulating apoptosis.
Wright
L C
LC
Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, NSW, Australia. lesleyw@icpmr.wsahs.nsw.gov.au
Obbink
K L
KL
Delikatny
E J
EJ
Santangelo
R T
RT
Sorrell
T C
TC
D016718:Arachidonic Acid / Q000378:metabolism; D002462:Cell Membrane / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D002478:Cells, Cultured; D005230:Fatty Acids, Nonesterified / Q000097:blood / Q000302:isolation & purification / Q000494:pharmacology; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D009682:Magnetic Resonance Spectroscopy; D008970:Molecular Weight; D009504:Neutrophils / Q000737:chemistry / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*; D009829:Oleic Acids / Q000378:metabolism; D010169:Palmitic Acids / Q000378:metabolism*; D012709:Serum Albumin / Q000494:pharmacology; D013229:Stearic Acids / Q000378:metabolism; D014280:Triglycerides / Q000378:metabolism*
D005230:Fatty Acids, Nonesterified; D008070:Lipopolysaccharides; D009829:Oleic Acids; D010169:Palmitic Acids; D012709:Serum Albumin; D013229:Stearic Acids; D014280:Triglycerides; D016718:Arachidonic Acid; C031183:stearic acid